Is the routine use of intravenous immunoglobulin treatment in neurologic disorders justified? No

Archives of Neurology

Volumn 56, Issue 8, 1999, Pages 1028-1032

  Karussis, Dimitrios ^a   Abramsky, Oded ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ALLERGIC REACTION; AUTOIMMUNE DISEASE; BACKACHE; BENIGN CHILDHOOD EPILEPSY; CLINICAL TRIAL; DRUG SAFETY; DRUG USE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE NECROSIS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYOKYMIA; MYOPATHY; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PARAPROTEINEMIA; POLYNEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STIFF MAN SYNDROME; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT PLANNING;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PERIODICITY; RISK ASSESSMENT;

EID: 0032839042     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.8.1028     Document Type: Review

References (91)

1. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712-716.
2. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neural Sci. 1998;153: 203-214.
3. Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol. 1990;82:163-169.
4. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol. 1997;100:151-157.
5. Brand A, Vuist WM, Van Schaik IN, Vermeulen M. In vitro investigation of immunoglobulin treatment mechanisms in autoimmune diseases. Clin Exp Rheumatol. 1996;14(suppl 15):S27-S30.
6. Kaveri S, Prasad N, Vassilev T, et al. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult Scler. 1997;3:121-128.
7. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin production by suppressing Ca(2+)-dependent signal transaction through Fc gamma receptors in B lymphocytes. Scand J Immunol. 1994; 40:37-42.
8. Mouthon L, Kaveri SV, Spalter SM, et al. Mechanisms of action of ntravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996;104(suppl 1):3-9.
9. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T-cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol. 1994;71:309-314.
10. Smiley JD, Talbert MG. Southwestern Internal Medicine Conference: high-dose intravenous gamma globulin therapy: how does it work? Am J Med Sci. 1995;309:295-303.
11. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol. 1996;104(suppl 1):21-25.
12. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97(suppl 1):79-83.
13. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety. 1993;9: 254-262.
14. Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol. 1996; 14(suppl 15):S53-S57.
15. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrambocytopenic purpura (ITP) and review of the literature. Haematologica. 1993;78:35-40.
16. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations: University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA. 1995;273:1865-1870.
17. Peetermans WE, Van Wijngaerden E, Knockaert DC. Aseptic meningitis and intravenous immunoglobulin therapy [letter, discussion]. Ann Intern Med. 1995;122:316;316-317.
18. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.
19. Meiner Z, Ben-Hur T, River Y, Reches A. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis [letter]. J Neurol Neurosurg Psychiatry. 1993;56: 830-831.
20. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K. High-dose intravenous IgG treatment and renal function. Lancet. 1991;337:457-458.
21. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-664.
22. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
23. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol. 1994;97 (suppl 1): 49-51.
24. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41:789-796.
25. Evoli A, Palmisani MT, Bartoccioni E, Padua L, Tonali P. High-dose intravenous immunoglobulin in myasthenia gravis. Ital J Neurol Sci. 1993;14:233-237.
26. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988; 295:438-443.
27. Liblau R, Gajdos P, Bustarret FA, el Habib R, Bach JF, Morel E. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991;11:128-131.
28. Soueidan SA, Dalakas MC. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr Res. 1993; 33(suppl 1):S95-S100.
29. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998;841:720-726.
30. Jongen JL, van Doorn PA, van der Meche FG. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol. 1998;245:26-31.
31. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993;50:837-840.
32. Uchiyama M, Ichikawa Y, Takaya M, Moriuchi J, Shimizu I, Arimori S. High-dose gammaglobulin therapy of generalized myasthenia gravis. Ann N Y Acad Sci. 1987;505:868-871.
33. van der Meche FG, Schmitz PI, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123-1129.
34. Mendell JR, Kissel JT, Kennedy MS, et al. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology. 1985;35:1551-1555.
35. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225-230.
36. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46:100-103.
37. Dawson WB, Phillips LH II. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Clin Neuropharmacol. 1995;18:377-390.
38. Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology. 1993;43: 1034-1036.
39. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology. 1993;43:872-875.
40. Enders U, Toyka KV, Hartung HP, Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol. 1997;76:112-116.
41. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-845.
42. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209-212.
43. van Doom PA. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1994;57(suppl):38-42.
44. Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM. 1995;88:493-502.
45. Vermeulen M, van Doom PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36-39.
46. Berger AR, Herskovitz S, Scelsa S. The restoration of IVIg efficacy by plasma exchange in CIDP. Neurology. 1995;45:1628-1629.
47. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48:321-328.
48. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology-1994;44:429-432.
49. Nobile Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993;43:537-544.
50. Leger JM, Younes Chennoufi AB, Chassande B, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994;57(suppl):46-49.
51. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high-dose intravenous immunoglobulins: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248-252.
52. Charles N, Benoit P, Vial C, Bierme T, Moreau T, Bady B. Intravenous immunoglobulin treatment in multifocal motor neuropathy [letter]. Lancet. 1992;340:182.
53. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 1994;51:861-864.
54. Bouche P, Moulonguet A, Younes Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995;59:38-44.
55. Elliot JL, Pestronk A. Progression of multifocal motor neuropathy during apparently succesful treatment with immunoglobulin. Neurology. 1994;44: 967-968.
56. Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990;40:212-214.
57. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neural. 1996;40:792-795.
58. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992;49:1233-1236.
59. Cook SD, Troiano R, Rohowsky-Kochan C, et al. Intravenous gamma globulin in progressive MS. Acta Neurol Scand. 1992;86:171-175.
60. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 1983;22:205-212.
61. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler. 1997;3:370-376.
62. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol. 1990;27:12-17.
63. Rodriguez M. Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells. Lab Invest. 1991;64:358-370.
64. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis [letter]. Ann Neurol. 1992;32:834-835.
65. Noseworthy J, Weinshenker B, O'Brien P, et al. Intravenous immunoglobulin does not reverse recently acquired, apparently permanent weakness in multiple sclerosis [abstract]. Ann Neurol. 1997;42:421.
66. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 1997;349: 589-593.
67. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS Study. Mult Scler. 1997;3:137-141.
68. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998; 50:1273-1281.
69. Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler. 1997;3:145-148.
70. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 1998;50:398-402.
71. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
72. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991; 91:162-168.
73. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry. 1992;55:60-62.
74. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876-879.
75. Ishii A, Hayashi A, Ohkoshi N, et al. Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome. J Neurol Neurosurg Psychiatry. 1994;57: 840-842.
76. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS): clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci. 1998;841:823-826.
77. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome, Neurology. 1996;47:678-683.
78. Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve. 1997;20:674-678.
79. Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve. 1994;17:1073-1075.
80. Counsell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology. 1994;44: 1184-1185.
81. Moll JW, Henzen-Logmans SC, Van der Meche FG, Vecht CH. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration [letter]. J Neurol Neurosurg Psychiatry. 1993;56:112.
82. Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388-392.
83. Amato AA, Cornman EW, Kissel JT. Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology. 1994;44:1652-1654.
84. van Engelen BG, Renier WO, Weemaes CM, Gabreels FJ, Meinardi H. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res. 1994;19:181-190.
85. van Engelen BG, Renier WO, Weemaes CM, Strengers PF, Bernsen PJ, Notermans SL. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. Eur J Pediatr. 1994;153: 762-769.
86. Duse M, Notarangelo LD, Tiberti S, Menegati E, Plebani A, Ugazio AG. Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol. 1996;104(suppl 1)71-76.
87. Gross Tsur V, Shalev RS, Kazir E, Engelhard D, Amir N. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand. 1993;88:204-209.
88. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol Suppl. 1992;33:94-97.
89. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991; 337:1137-1139.
90. Jayne DR, Lockwood CM. High-dose pooled immunoglobulin in the therapy of systemic vasculitis. Trans Assoc Am Physicians. 1991;104:304-312.
91. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy [letter]. Muscle Nerve. 1994;17:1494-1495.